Research could help fine-tune cancer treatment

May 25, 2018, University of East Anglia
Research could help fine-tune cancer treatment
Credit: University of East Anglia

Cancer therapies that cut off blood supply to a tumour could be more effective in combination with existing chemotherapeutic drugs—according to new research from the University of East Anglia.

New research published today in the journal EMBO Reports reveals that tumour growth is better-reduced in mice when the expression of a particular called Beta3-integrin is targeted in combination with drugs that are already used in .

It is hoped that the findings could help fine-tune treatment for patients and revitalise an interest in the use of microtubule targeting agents (MTAs) which are commonly used as chemotherapies in cancer patients.

Lead researcher Dr. Stephen Robinson from UEA's School of Biological Sciences, said: "Tumours must recruit their own to grow beyond a very small size and this process is called angiogenesis.

"Anti-angiogenic drugs stop tumours from growing their own , and this in turn can slow the growth of the cancer, or shrink it. Targeting angiogenesis is therefore seen as crucial in many anti-cancer strategies.

"However many anti-angiogenetic therapies target proteins that help the functioning of a patient's normal blood supply—and this can lead to nasty side effects including haemorrhage, strokes, , and fatigue."

The research team has long looked at Beta3-integrin as a better anti-angiogenic target because the protein is not expressed in normal blood vessels, but is expressed in tumour blood vessels. This reduces the potential for unwanted side effects.

Now the team has shown that targeting Beta3-integrin in combination with microtubule targeting agents, which are widely used in cancer patients, works better than targeting Beta3-integrin alone. Microtubules are protein structures in cells that help them move and divide.

Specifically, the Robinson lab looked at how Beta3-integrin and microtubules interact with one another in the cells that line blood vessels (endothelial cells), and showed that microtubules behave differently when Beta3-integrin levels are reduced; the microtubules become more sensitive to the chemotherapies that are used to hit them.

Dr. Robinson said: "This protein, Beta3-integrin, has been the focus of drug design over the last two decades because its expression is vastly increased in during blood vessel recruitment to tumours.

"We found that targeting the protein Beta3-integrin in combination with the use of microtubule targeting agents (MTAs) could be a good way to stop tumours recruiting a supply to grow.

"This is really important because MTAs are already in clinic and commonly used as chemotherapies such as paclitaxel in cancer patients. Meanwhile Beta3-integrin inhibitors have been at the centre of cancer drug design for over 20 years and are well-tolerated in clinical trials.

"We hope that this research could revitalise interest in this sort of therapy and lead to a re-purposing of MTAs as anti-angiogenic inhibitors, in combination with targeting Beta3 integrin."

'The β3-integrin endothelial adhesome regulates dependent cell migration' is published in the journal EMBO Reports on May 25, 2018.

Explore further: Scientists make advance in cancer research

More information: Samuel J Atkinson et al, The β3‐integrin endothelial adhesome regulates microtubule‐dependent cell migration, EMBO reports (2018). DOI: 10.15252/embr.201744578

Related Stories

Scientists make advance in cancer research

January 3, 2014
A protein that has been at the centre of cancer drug design for the last 20 years should not be given up on according to new research from the University of East Anglia (UEA). The most advanced version of αvβ3-integrin ...

Study may point to new treatment approach for ASD

November 17, 2017
Using sophisticated genome mining and gene manipulation techniques, researchers at Vanderbilt University Medical Center (VUMC) have solved a mystery that could lead to a new treatment approach for autism spectrum disorder ...

Study pinpoints key protein in a severe vascular disease

February 9, 2016
The aorta, the body's largest artery, is like a hose through which our blood flows. When the hose is squeezed, the pump (i.e., the heart) is forced to work harder. In a new study, Yale researchers investigated factors that ...

New strategy to attack tumor-feeding blood vessels

June 6, 2011
Scientists at the Walter and Eliza Hall Institute have discovered a key molecule needed to kill the blood vessels that supply tumours.

Recommended for you

'Kiss of death' cancer: How computational geeks may have uncovered a therapy for a deadly disease

June 19, 2018
It's called the 'kiss of death'. Triple negative breast cancer has no targeted drug therapy and, as such, the only hope for these patients is chemotherapy. Triple negative breast cancer is aggressive and deadly. Patients ...

Team discovers gene mutations linked to pancreatic cancer

June 19, 2018
Six genes contain mutations that may be passed down in families, substantially increasing a person's risk for pancreatic cancer. That's according to Mayo Clinic research published in the June 19 edition of the JAMA. However, ...

Breast cancer could be prevented by targeting epigenetic proteins, study suggests

June 19, 2018
Researchers at the Princess Margaret Cancer Centre in Toronto have discovered that epigenetic proteins promote the proliferation of mammary gland stem cells in response to the sex hormone progesterone. The study, which will ...

Ovarian cancer cells switched off by 'unusual' mechanism

June 19, 2018
Scientists at the Ovarian Cancer Action Research Centre at Imperial College London have discovered a mechanism that deactivates ovarian cancer cells.

Targeting the engine room of the cancer cell

June 18, 2018
Researchers at Columbia University Irving Medical Center (CUIMC) have developed a highly innovative computational framework that can support personalized cancer treatment by matching individual tumors with the drugs or drug ...

Study suggests well-known growth suppressor actually fuels lethal brain cancers

June 18, 2018
Scientists report finding a potentially promising treatment target for aggressive and deadly high-grade brain cancers like glioblastoma. But they also say the current lack of a drug that hits the molecular target keeps it ...

0 comments

Please sign in to add a comment. Registration is free, and takes less than a minute. Read more

Click here to reset your password.
Sign in to get notified via email when new comments are made.